Paxalisib blocks the PI3K/mTOR pathway, which plays a role in cancer cell growth and survival, but researchers have also ...

Paxalisib, first studied in brain cancer, may help HR+ breast tumors respond to CDK4/6 inhibitors again, based on early lab data.

FDA cleared BRAVNETSA for adult SSTR+ GEP-NETs spanning foregut, midgut, and hindgut sites, adding a second approved lutetium Lu 177 dotatate radiopharmaceutical option. ANDA-based approval ...

The investigational drug, first developed for brain cancer, is being tested to see whether it can make resistant tumors respond to treatment again.

For years, much of cancer research has focused on understanding the tumor itself — how cancer cells grow, what causes them to change and how those cells can be targeted with treatment. But researchers ...

After facing multiple cancers and hospice care, April Floyd credits her service dog Onyx with helping her find comfort, ...

Concurrent chemoradiation followed by durvalumab yields objective responses in only ~30% of stage III unresectable NSCLC, while toxicity and normal-tissue constraints preclude meaningful radiation ...

Cancer care complexity arises from multiple disease subtypes, expanding therapeutic sequences, and individualized constraints from comorbidities, concurrent medications, and drug–drug interactions.

An estimated 70% of patients with stage 3 lung cancer do not see their tumors respond to standard treatment. An expert explains why, and what a new approach aims to change.

I have been living with stage IV kidney cancer for more than ten years. By now, I have had more CT scans, MRIs, PET scans, blood tests and follow-up appointments than I could ever count. You would ...

Independent radiology review showed 94% ORR (15% CR) in 94 TKI-naïve ROS1+ NSCLC patients receiving 100 mg daily, with median DoR and PFS not reached. Central nervous system efficacy was robust: 10/10 ...

FDA approves Inluriyo plus Verzenio for adults with ESR1-mutated, ER-positive, HER2-negative advanced or metastatic breast ...